Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Basilico

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Expert Opinion on Investigational Drugs|February 1, 2017
Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphomaAndrea Ferrario, Michele Merli, Claudia Basilico, et al.
Therapeutic Advances in Hematology|April 24, 2013
Novel agents in indolent lymphomasMichele Merli, Andrea Ferrario, Claudia Basilico, et al.
Leukemia & Lymphoma|December 3, 2016
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletionChiara Pessina, Claudia Basilico, Angelo Genoni, et al.
Hematological Oncology|June 4, 2014
PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilizationGiuseppe Rossi, Cristina Skert, Enrico Morello, et al.
Journal of Geriatric Oncology|October 24, 2020
Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL)Erika Borlenghi, Chiara Pagani, Patrizia Zappasodi, et al.
Cancers|January 23, 2024
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination-Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica LombardaGiuseppe Rossi, Erika Borlenghi, Patrizia Zappasodi, et al.
American Journal of Hematology|November 23, 2017
Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL)Erika Borlenghi, Chiara Pagani, Patrizia Zappasodi, et al.
American Journal of Hematology|December 11, 2024
Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical TrialRoberto Cairoli, Arianna Gatti, Giovanni Grillo, et al.
Cancer|August 21, 2025
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experienceRoberto Cairoli, Lorenzo Del Castello, Silvia Imbergamo, et al.
Annals of Hematology|May 24, 2025
Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life studyLuana Fianchi, Alfonso Piciocchi, Fabio Guolo, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Expert Opinion on Investigational Drugs|February 1, 2017
Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphomaAndrea Ferrario, Michele Merli, Claudia Basilico, et al.
Therapeutic Advances in Hematology|April 24, 2013
Novel agents in indolent lymphomasMichele Merli, Andrea Ferrario, Claudia Basilico, et al.
Leukemia & Lymphoma|December 3, 2016
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletionChiara Pessina, Claudia Basilico, Angelo Genoni, et al.
Hematological Oncology|June 4, 2014
PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilizationGiuseppe Rossi, Cristina Skert, Enrico Morello, et al.
Journal of Geriatric Oncology|October 24, 2020
Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL)Erika Borlenghi, Chiara Pagani, Patrizia Zappasodi, et al.
Cancers|January 23, 2024
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination-Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica LombardaGiuseppe Rossi, Erika Borlenghi, Patrizia Zappasodi, et al.
American Journal of Hematology|November 23, 2017
Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL)Erika Borlenghi, Chiara Pagani, Patrizia Zappasodi, et al.
American Journal of Hematology|December 11, 2024
Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical TrialRoberto Cairoli, Arianna Gatti, Giovanni Grillo, et al.
Cancer|August 21, 2025
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experienceRoberto Cairoli, Lorenzo Del Castello, Silvia Imbergamo, et al.
Annals of Hematology|May 24, 2025
Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life studyLuana Fianchi, Alfonso Piciocchi, Fabio Guolo, et al.
Pageof 2